leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 13:53:20 - browse：4

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： TytoCare raises $49 million to build out AI

hotspot

WSS

What Henrietta Lacks settlement says about racism in medicine

Humana, CVS hope to turn members into patients at clinics

OTC birth control: A brief history of over the counter pill design

New oral drug delivery patch is modeled after octopus tentacles

Medicare innovation center doesn’t save money, experts say

WHO recommends second malaria vaccine

entertainment

leisure time

entertainment

Psychedelics group wrestles with new pharma identity

Nearly two

Walensky prepares to leave CDC — and Congress — behind

Congress extends some pandemic preparedness programs

How one medical school became remarkably diverse

ProMED, early warning system on disease outbreaks, in peril

Anesthesiologist group: stop taking Ozempic before surgery

Will an HIV vaccine ever be a reality?

The cancer drug shortage isn’t new — and neither are the solutions

Health insurers' Q3 question: how much care are people getting?

focus

TytoCare raises $49 million to build out AI

Humana, CVS hope to turn members into patients at clinics

My superpower is killing ticks

Congress extends some pandemic preparedness programs

For BCIs, commercial hurdles may be bigger than scientific ones

Humana, CVS hope to turn members into patients at clinics

leisure time

entertainment

hotspot

Wikipedia